INSPIRE
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
- NCT04216290 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on INSPIRE (durvalumab, gemcitabine hydrochloride and 3 more in Bladder Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INSPIRE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Bladder Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8
- Interventions
- Biopsy of Bladder; Biospecimen Collection; Cisplatin; Computed Tomography; Cystoscopy; Durvalumab; Fluorouracil; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Mitomycin; Patient Observation; Radiation Therapy
- Arms
- Step 1, Arm C (durvalumab, radiation therapy, chemotherapy) · Experimental
- Step 1, Arm D (radiation therapy, chemotherapy) · Active comparator
- Step 2, Arm E (durvalumab) · Experimental
- Step 2, Arm F (observation) · Active comparator
- Enrollment
- 11
- Primary outcomes
- Clinical complete response (CR)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Mar 17, 2021
- Primary completion
- Feb 4, 2026
- Results posted
- No
- Registry record
- NCT04216290 · updated May 22, 2026